Position statement of the Brazilian society of Rheumatology on mesna use as a preventive therapy for bladder disease in patients with systemic autoimmune diseases and systemic vasculitis under cyclophosphamide treatment.

Alexandre Wagner Silva de SouzaJoão Gabriel DantasAna Carolina de Oliveira E Silva MontandonAna Luísa CalichAndrea Rocha de Saboia Mont' AlverneAndrese Aline GasparinDante BianchiEmily Figueiredo Neves YukiNathalia SacilottoEdgard Torres Dos Reis NetoOdirlei André MonticieloIvanio Alves Pereira

Published in: Advances in rheumatology (London, England) (2024)

The current evidence was found to be insufficient to support the routine use of mesna for the prophylaxis of hemorrhagic cystitis and bladder cancer in patients being treated for systemic autoimmune diseases and systemic vasculitis with cyclophosphamide. The use may be considered for selected cases.

Keyphrases

end stage renal disease
newly diagnosed
low dose
high dose
chronic kidney disease
ejection fraction
prognostic factors
peritoneal dialysis
rheumatoid arthritis
systemic lupus erythematosus
clinical practice
combination therapy
juvenile idiopathic arthritis